Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, PR China.
Eur J Hum Genet. 2012 Jul;20(7):790-5. doi: 10.1038/ejhg.2011.276. Epub 2012 Jan 25.
Survivin is an inhibitor of apoptosis protein and has a crucial role in the development of cancer. The survivin -31G>C (rs9904341) promoter polymorphism influences survivin expression and has been implicated in cancer risk. However, conflicting results have been published from studies on the association between survivin -31G>C polymorphism and the risk of cancer. To clarify the role of this polymorphism in cancer, we performed a meta-analysis of all available and relevant published studies, involving a total of 3485 cancer patients and 3964 control subjects. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of the associations. The overall results indicated that the variant genotypes were associated with a significantly increased cancer risk (CC vs GG: OR=1.58, 95% CI=1.20-2.10; CC/GC vs GG: OR=1.23, 95% CI=1.00-1.51; CC vs GG/GC: OR=1.51, 95% CI=1.23-1.85). In the stratified analyses, significantly increased risk was associated with the Asian populations (CC vs GG: OR=1.67, 95% CI=1.16-2.40; CC vs GG/GC: OR=1.50, 95% CI=1.17-1.91). We also performed the analyses by cancer type, and no statistical association was observed. The results suggest that the survivin -31G>C promoter polymorphism might be associated with an increased risk of cancer, especially in the Asian populations.
生存素是一种凋亡抑制蛋白，在癌症的发生发展中起着关键作用。生存素-31G>C（rs9904341）启动子多态性影响生存素的表达，并与癌症风险有关。然而，关于生存素-31G>C 多态性与癌症风险之间的关联的研究结果存在冲突。为了阐明该多态性在癌症中的作用，我们对所有可用的相关研究进行了荟萃分析，共纳入了 3485 例癌症患者和 3964 例对照。使用比值比（ORs）和 95%置信区间（CIs）来评估关联的强度。总体结果表明，变异基因型与癌症风险显著增加相关（CC 与 GG：OR=1.58，95%CI=1.20-2.10；CC/GC 与 GG：OR=1.23，95%CI=1.00-1.51；CC 与 GG/GC：OR=1.51，95%CI=1.23-1.85）。在分层分析中，与亚洲人群相关的风险显著增加（CC 与 GG：OR=1.67，95%CI=1.16-2.40；CC 与 GG/GC：OR=1.50，95%CI=1.17-1.91）。我们还按癌症类型进行了分析，但未观察到统计学关联。结果表明，生存素-31G>C 启动子多态性可能与癌症风险增加相关，尤其是在亚洲人群中。
